[{"orgOrder":0,"company":"Akorn Pharmaceuticals","sponsor":"Prestige Consumer Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Divestment","leadProduct":"Sodium Carboxymethylcellulose","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Akorn Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.23000000000000001,"dosageForm":"Eye Drop","sponsorNew":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Akorn Pharmaceuticals \/ Prestige Consumer Healthcare"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"L-Lactic Acid","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Galderma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Galderma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Sodium Carboxymethylcellulose

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Sculptra is the first and original injectable collagen stimulator containing microparticles of unique poly-L-lactic acid (PLLA-SCA) which gradually revitalizes the skin’s structural foundation.

                          Brand Name : Sculptra

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 30, 2023

                          Lead Product(s) : L-Lactic Acid,Sodium Carboxymethylcellulose

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The Consumer Health business primarily consists of the following over-the-counter brands: TheraTears , Diabetic Tussin , MagOx , Multi-betic , and Zostrix.

                          Brand Name : TheraTears

                          Molecule Type : Small molecule

                          Upfront Cash : $230.0 million

                          May 27, 2021

                          Lead Product(s) : Sodium Carboxymethylcellulose

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Prestige Consumer Healthcare

                          Deal Size : $230.0 million

                          Deal Type : Divestment

                          blank